MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms

This LCD covers multi-gene non‑NGS panel testing and limited sequential single‑gene testing for the diagnostic evaluation of BCR‑ABL‑negative MPNs (classical and selected non‑classical subtypes) when performed per WHO/ICC diagnostic criteria. Tests must follow BCR‑ABL assessment (except when only PV is suspected), include the minimum necessary genes for the suspected subtype (e.g., JAK2, CALR, MPL), have demonstrated analytical and clinical validity with a completed technical assessment, and are covered for diagnosis only (not for MRD or test‑of‑cure); NGS testing for myeloid neoplasms and MDS/MPN entities is handled under separate policy L38176.

"Multi-gene non-next generation sequencing (non-NGS) panels are covered for diagnostic workup of BCR-ABL-negative myeloproliferative neoplasms (MPNs), including classical (PV, ET, PMF) and non-class..."

Sign up to see full coverage criteria, indications, and limitations.